- Home
- CWAN vs CORT Comparison
CWAN vs CORT Comparison
Compare CWAN & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CWAN
- CORT
- Stock Information
- Founded
- CWAN 2004
- CORT 1998
- Country
- CWAN United States
- CORT United States
- Employees
- CWAN N/A
- CORT N/A
- Industry
- CWAN Computer Software: Prepackaged Software
- CORT Biotechnology: Pharmaceutical Preparations
- Sector
- CWAN Technology
- CORT Health Care
- Exchange
- CWAN Nasdaq
- CORT Nasdaq
- Market Cap
- CWAN 6.1B
- CORT 7.5B
- IPO Year
- CWAN 2021
- CORT N/A
- Fundamental
- Price
- CWAN $22.14
- CORT $72.27
- Analyst Decision
- CWAN Buy
- CORT Strong Buy
- Analyst Count
- CWAN 10
- CORT 4
- Target Price
- CWAN $31.50
- CORT $142.00
- AVG Volume (30 Days)
- CWAN 4.6M
- CORT 1.6M
- Earning Date
- CWAN 07-30-2025
- CORT 07-28-2025
- Dividend Yield
- CWAN N/A
- CORT N/A
- EPS Growth
- CWAN N/A
- CORT 8.36
- EPS
- CWAN 1.71
- CORT 1.14
- Revenue
- CWAN $475,948,000.00
- CORT $685,446,000.00
- Revenue This Year
- CWAN $63.43
- CORT $35.83
- Revenue Next Year
- CWAN $29.94
- CORT $35.24
- P/E Ratio
- CWAN $12.92
- CORT $63.26
- Revenue Growth
- CWAN 23.21
- CORT 30.93
- 52 Week Low
- CWAN $17.63
- CORT $29.42
- 52 Week High
- CWAN $35.71
- CORT $117.33
- Technical
- Relative Strength Index (RSI)
- CWAN 46.90
- CORT 49.68
- Support Level
- CWAN $21.39
- CORT $68.52
- Resistance Level
- CWAN $22.47
- CORT $75.95
- Average True Range (ATR)
- CWAN 0.67
- CORT 2.66
- MACD
- CWAN 0.01
- CORT -0.13
- Stochastic Oscillator
- CWAN 60.82
- CORT 42.13
About CWAN Clearwater Analytics Holdings Inc.
Clearwater Analytics describes its mission as aiming to be the world's most trusted and comprehensive technology platform for the entire investment cycle. Clearwater has historically focused on back-office functions such as investment accounting, but with acquisitions such Enfusion, Beacon, and Bistro, the firm has broadened its focus with front-office and middle-office capabilities. Clearwater primarily serves insurance companies, asset managers, hedge funds, and corporate treasuries. Pro forma for Enfusion, about 76% of Clearwater's revenue is generated in the US.
About CORT Corcept Therapeutics Incorporated
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.